A collaborative initiative to advance corporate board diversity through partnerships and more.

Apply today to join an unparelled network of BIO Members and to benefit from a number of resources and event discounts. BIO membership is available only to bona fide organizations that promote ...

Explore the webinar opportunities for interactive, online learning about emerging issues in biotechnology public policy, scientific progress, and raising capital, plus methods to benefit from BIO’s ...

Explore the webinar opportunities for interactive, online learning about emerging issues in biotechnology public policy, scientific progress, and raising capital, plus methods to benefit from BIO’s ...

At its simplest, biotechnology is technology based on biology - biotechnology harnesses cellular and biomolecular processes to develop technologies and products that help improve our lives and the ...

BIO President & CEO John F. Crowley released the following statement: “A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic ...

Jeff is a registered patent attorney and an intellectual property and innovation policy professional with a unique combination of training and real-world experience. Jeff has done policy work for ...

Kevin E. Noonan is co-Chair of MBHB’s Biotechnology and Pharmaceuticals Practice Group. Dr. Noonan is an experienced patent lawyer, molecular biologist and renowned thought leader in biotechnology and ...

BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities. "Manufacturers should have the choice to effectuate ...

Today, we explore BIO’s recommendations for how CMS can safeguard patient access under Medicare Part D, along with insights on a California Supreme Court case that could affect the complex drug ...

9:00 AM - 9:10 AM (EDT), Tuesday, November 19, 2024 ...

WASHINGTON – BIO President & CEO John F. Crowley released the following statement on the results of the 2024 U.S. election: “We look forward to working closely with President-elect Trump, his incoming ...